Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + carboplatin + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Camrelizumab + carboplatin + paclitaxel is a combination regimen used primarily as first-line therapy for advanced squamous non-small cell lung cancer (NSCLC) and has also been studied in other cancers such as esophageal squamous cell carcinoma. Camrelizumab is a humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2 and thereby enhancing T-cell mediated antitumor immune responses. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis of rapidly dividing cells. Paclitaxel is a microtubule inhibitor that disrupts mitosis by stabilizing microtubules, preventing their depolymerization. The combination leverages the immunomodulatory effects of camrelizumab with the cytotoxic actions of chemotherapy to improve survival outcomes in patients with advanced cancers[1][4][5][7].
- Other names
- camrelizumab + carboplatin + paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on camrelizumab + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + carboplatin + paclitaxel.